Physician profile
Daniel J Kim
NPI 1124469788
$54,644.25
in general payments reported to CMS, 2019-2025
11 companies · $34K in 2025
The $34K reported for 2025 was more than what 94% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,669 · 2020: $358 · 2021: $1,217 · 2022: $1,219 · 2023: $1,846 · 2024: $12K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $33K · Travel and Lodging: $13K · Food and Beverage: $2,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $32,900.00 |
| Travel and Lodging | $12,508.36 |
| Food and Beverage | $2,772.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $50,745.47 | 2019-2025 | Mako, Aequalis, Triathlon |
| Smith+Nephew, INC. | $2,695.76 | 2019-2024 | Real Intelligence |
| Alphatec Spine, INC | $589.23 | 2022 | |
| Medical Device Business Services, INC. | $184.97 | 2021-2025 | Velys |
| Amgen INC. | $145.03 | 2021-2024 | Repatha, Prolia, Evenity |
| Blue Earth Diagnostics | $98.95 | 2021 | |
| Integra Lifesciences Corporation | $81.39 | 2022 | |
| Glaxosmithkline, LLC. | $38.13 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $29.98 | 2023 | Proclaim |
| Zimmer Biomet Holdings, INC. | $19.82 | 2021 | |
| Depuy Synthes Sales INC. | $15.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.